0801.HK - Golden Meditech Holdings Limited

HKSE - HKSE Delayed Price. Currency in HKD
0.970
+0.010 (+1.04%)
As of 3:55PM HKT. Market open.
Stock chart is not supported by your current browser
Previous Close0.970
Open0.960
Bid0.940 x 0
Ask0.980 x 0
Day's Range0.960 - 0.990
52 Week Range0.720 - 1.100
Volume360,000
Avg. Volume1,766,044
Market Cap2.829B
Beta (3Y Monthly)0.40
PE Ratio (TTM)N/A
EPS (TTM)-0.232
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2018-03-07
1y Target EstN/A
  • PR Newswire18 days ago

    Golden Meditech Announces FY2018/2019 Annual Results

    Growth Achieved in Revenue and Business Diversification Synergies from Each Business Segment, Steady Expansion in New Biomedical Businesses HONG KONG , June 28, 2019 /PRNewswire/ -- Golden Meditech Holdings ...

  • PR Newswire2 months ago

    Five Directors of Golden Meditech Voluntarily Resigned Due to Personal Reasons

    HONG KONG, May 24, 2019 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announced that, Mr Kam Yuen ("Mr Kam") and Mr Kong Kam Yu ("Mr Kong"), executive directors of the Company, Ms Zheng Ting ("Ms Zheng"), non-executive director, Professor Gu Qiao and Professor Cao Gang, independent non-executive directors, voluntarily resigned due to personal reasons.

  • PR Newswire3 months ago

    Golden Meditech and HKBU Team Up to Conduct Cell Therapy Research

    HONG KONG, April 17, 2019 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801) ("Golden Meditech"), a leading integrated healthcare enterprise in China, announced that it has formed a collaboration with the Department of Biology of Hong Kong Baptist University ("HKBU") to conduct in-depth research in the area of cell therapy, particularly treating neurodegenerative diseases with stem cells. Neurodegenerative diseases are mainly caused by the death or degeneration of nerve cells in the brain. According to statistics published in 2015, over 100 million people worldwide suffer from neurodegenerative diseases.

  • PR Newswire8 months ago

    Golden Meditech Announces FY2018/2019 Interim Results

    Focusing on Business Diversification Strategies and Achieved Double-Digit Group Revenue Growth Newly-established Businesses in Healthcare Services Grew Rapidly and Strategic Investment Projects On-track ...

  • Reuters8 months ago

    BRIEF-Golden Meditech Holdings Posts HY Loss For Period Of HK$168.5 Mln

    Nov 26 (Reuters) - Golden Meditech Holdings Ltd: * HY REVENUE HK$163.9 MILLION VERSUS HK$117.1 MILLION * HY LOSS FOR PERIOD HK$168.5 MILLION VERSUS LOSS HK$117 MILLION Source text for Eikon: Further company ...

  • Reuters11 months ago

    BRIEF-Golden Meditech Announces Termination Of LP Transfer Agreement

    July 31 (Reuters) - Golden Meditech Holdings Ltd: * GOLDEN MEDITECH HOLDINGS LTD ANNOUNCES TERMINATION OF LP TRANSFER AGREEMENT IN RELATION TO ACQUISITION OF INTEREST OF A LIMITED PARTNER IN A PRC Source ...